Previous section: Background
Medical Countermeasure Resources
FDA obligated $169.5 million in FY 2013 to support CBRN and pandemic influenza-related medical countermeasure activities (Table 1). These resources comprised a combination of base funding and no-year funding.
|FY 13 Actuals||FY 13 FTE Actuals|
|CBRN Base Funding||$62.3||317|
|Pandemic Influenza Base Funding||$32.1||158|
|MCMi Base Funding||$21.8||77|
FDA obligated $116.2 million from its FY 2013 base resources to support CBRN and pandemic influenza-related medical countermeasure activities. This funding included $62.3 million for CBRN preparedness activities, $32.1 million for pandemic influenza preparedness activities, and $21.8 million for the MCMi. (10)
This funding supported 452 FTEs as well as a $0.9 million investment in the MCMi regulatory science program.
FDA received $170 million, one-time funding from HHS to immediately commence MCMi activities at the end of FY 2010 when the MCMi was launched. In FY 2013, FDA obligated $53.3 million of the no-year funding to support MCMi activities. (11) This funding supported 8 FTEs as well as regulatory science projects and infrastructure for the MCMi Regulatory Science Program and other non-payroll MCMi costs (e.g., professional development).
(10) In FY 2013, Congress provided FDA with $23.5 million base funding for the MCMi, however, as a result of reductions experienced with the sequester and rescission in FY 2013, the total estimated FY 2013 MCMi budget authority is $21.8 million.
(11) FDA expended $49.9 million of the $170 million no-year funding during FY 2011, and $54.6 million during FY 2012. FDA anticipates expending the remaining balance of the no-year funding (approximately $12.2 million) through FY 2015.
Next section: FY 2013 Objectives, Activities, and Achievements